DE69637930D1 - Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität - Google Patents

Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität

Info

Publication number
DE69637930D1
DE69637930D1 DE69637930T DE69637930T DE69637930D1 DE 69637930 D1 DE69637930 D1 DE 69637930D1 DE 69637930 T DE69637930 T DE 69637930T DE 69637930 T DE69637930 T DE 69637930T DE 69637930 D1 DE69637930 D1 DE 69637930D1
Authority
DE
Germany
Prior art keywords
rsv
human
monoclonal antibodies
high affinity
proteins specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637930T
Other languages
English (en)
Inventor
Peter Brams
Soulaima Salim Chamat
Li-Zhen Pan
Edward E Walsh
Cheryl Janne Heard
Roland Anthony Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DE69637930D1 publication Critical patent/DE69637930D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
DE69637930T 1995-06-07 1996-06-06 Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität Expired - Lifetime DE69637930D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/488,376 US5811524A (en) 1995-06-07 1995-06-07 Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
PCT/US1996/010070 WO1996040252A1 (en) 1995-06-07 1996-06-06 High affinity human monoclonal antibodies specific for rsv f-protein

Publications (1)

Publication Number Publication Date
DE69637930D1 true DE69637930D1 (de) 2009-06-25

Family

ID=23939500

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637930T Expired - Lifetime DE69637930D1 (de) 1995-06-07 1996-06-06 Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität

Country Status (23)

Country Link
US (11) US5811524A (de)
EP (2) EP2095827A1 (de)
JP (1) JP3771267B2 (de)
KR (1) KR100490687B1 (de)
CN (2) CN1680447A (de)
AR (1) AR003423A1 (de)
AT (1) ATE431159T1 (de)
AU (1) AU717061B2 (de)
BR (1) BR9608884A (de)
CA (1) CA2223033A1 (de)
CO (1) CO4480110A1 (de)
DE (1) DE69637930D1 (de)
HK (1) HK1015282A1 (de)
IL (1) IL122404A0 (de)
MX (2) MXPA01011457A (de)
MY (1) MY137299A (de)
NO (1) NO324047B1 (de)
NZ (2) NZ310847A (de)
RS (1) RS50157B (de)
SA (1) SA96170384B1 (de)
UY (1) UY24255A1 (de)
WO (1) WO1996040252A1 (de)
ZA (1) ZA964434B (de)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
FR2758331B1 (fr) * 1997-01-14 1999-03-05 Univ Bourgogne Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6900299B1 (en) * 1999-03-11 2005-05-31 University Of South Florida Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
AR030019A1 (es) * 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
GB9918788D0 (en) * 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DE60142614D1 (de) 2000-01-27 2010-09-02 Medimmune Inc Inität
EP1255560B1 (de) 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
US7700735B2 (en) * 2000-03-01 2010-04-20 Medimmune, Llc High potency recombinant antibodies and method for producing them
JP2003531866A (ja) * 2000-05-03 2003-10-28 メディミューン，インコーポレイテッド 抗体を用いた呼吸器疾患の組合せ治療法
TWI327599B (en) * 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
EP1370292A1 (de) 2001-01-31 2003-12-17 Idec Pharmaceuticals Corporation Verwendung von cd23 antagonisten zur behandlung von neoplastischen erkrankungen
JP2005508284A (ja) * 2001-03-23 2005-03-31 ジェネンテック・インコーポレーテッド 免疫反応調節のためのｏｐｇリガンドの使用
AU2002307037B2 (en) * 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US6955717B2 (en) 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
CA2452005C (en) * 2001-07-10 2011-03-15 Idec Pharmaceutical Corporation Inhibition of apoptosis process and improvement of cell performance
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7306919B1 (en) * 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
EP1501870A4 (de) * 2001-11-02 2006-05-03 Centocor Inc Rsv proteine, antikörper, zusammensetzungen, verfahren und verwendungen
CA2476232A1 (en) * 2002-02-11 2003-08-21 Alexion Pharmaceuticals, Inc. Production of human antibodies in immunodeficient, non-human, mammalian hosts
US20050208479A1 (en) * 2002-02-11 2005-09-22 Bowdish Katherine S Human antibodies for use as a therapeutic agent against vaccinia or small pox
WO2003083114A1 (en) * 2002-03-28 2003-10-09 Yamanouchi Pharmaceutical Co., Ltd. Antiopoietin-related growth factor
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004001035A1 (en) * 2002-06-21 2003-12-31 Centocor, Inc. Method for generating monoclonal antibodies
WO2004010935A2 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
KR100604038B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 중쇄 발현벡터
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
JP2006520194A (ja) * 2003-01-27 2006-09-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｉｇｓｆ９およびｌｉｖ−１を使用して癌を処置するための組成物および方法
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
EP2248899B8 (de) * 2003-03-19 2015-07-15 Biogen MA Inc. NOGO Rezeptor bindendes Protein
JPWO2004087761A1 (ja) * 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
CA2530172A1 (en) 2003-06-27 2005-02-10 Abgenix, Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005037999A2 (en) * 2003-10-14 2005-04-28 Biogen Idec Ma Inc. Treatment of cancer using antibodies to lrrc15
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US20060246079A1 (en) 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
WO2005081749A2 (en) * 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
EP1687029A4 (de) * 2003-11-14 2007-05-30 Avanir Pharmaceuticals Neutralisierende menschliche antikörper gegen anthrax-toxin, erzeugt durch recall-technologie
CN1914226B (zh) * 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
US20050260679A1 (en) 2004-03-19 2005-11-24 Sirid-Aimee Kellerman Reducing the risk of human anti-human antibodies through V gene manipulation
AU2005258335B2 (en) * 2004-06-24 2011-03-17 Biogen Ma Inc. Treatment of conditions involving demyelination
EP2329714A1 (de) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Einfluss von TAJ in den neuronalen Funktionen
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
CN101137673B (zh) 2005-01-05 2013-12-04 比奥根艾迪克Ma公司 Cripto结合分子
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
CA2611519A1 (en) * 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
US20100304358A1 (en) * 2005-08-15 2010-12-02 Shuming Nie Methods of identifying biological targets and instrumentation to identify biological targets
AU2006311828B2 (en) 2005-11-04 2013-07-11 Biogen Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
AU2006318580A1 (en) * 2005-11-21 2007-05-31 Merck Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
WO2007064882A2 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
PL1974017T5 (pl) * 2005-12-09 2023-10-23 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała
CA2633601C (en) * 2005-12-16 2015-06-30 Ribovax Biotechnologies Sa Methods for obtaining immortalized antibody secreting cells
US8669345B2 (en) 2006-01-27 2014-03-11 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
TW200813086A (en) 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2740744B1 (de) 2007-01-09 2018-03-28 Biogen MA Inc. Sp35-Antikörper und Verwendungen dafür
AU2008224259A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
JP5932217B2 (ja) * 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
CA2704134A1 (en) * 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
ES2883176T3 (es) 2007-11-08 2021-12-07 Prec Biologics Inc Anticuerpos monoclonales recombinantes y antígenos correspondientes para cánceres de colon y de páncreas
WO2009067820A1 (en) * 2007-11-27 2009-06-04 The University Of British Columbia 14-3-3 antagonists for the prevention and treatment of arthritis
KR100938998B1 (ko) * 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
DK2982695T3 (da) * 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2145621A1 (de) 2008-07-16 2010-01-20 Stephan Lück Verhinderung der Dehydrierung und Reduzierung der gluconeogenetischen Verluste von Aminosäuren durch Propan-1,2,3-Triol
JP5575377B2 (ja) * 2008-07-18 2014-08-20 シスメックス株式会社 抗ｒｓウイルスモノクローナル抗体を用いたｒｓウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗ｒｓウイルスモノクローナル抗体
EP2373689A1 (de) 2008-12-12 2011-10-12 MedImmune, LLC Kristalle und struktur einer humanen igg-fc-variante mit verst?rkter fcrn-bindung
WO2010078526A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
WO2010139808A2 (en) * 2009-06-05 2010-12-09 Ablynx Nv IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (hRSV) AND POLYPEPTIDES COMPRISING THE SAME FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS
LT3178490T (lt) 2009-07-15 2022-07-25 Glaxosmithkline Biologicals S.A. Rsv f baltymų kompozicijos ir jų gamybos būdai
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
WO2011034582A2 (en) * 2009-09-16 2011-03-24 Duke University Hiv-1 antibodies
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2507262A1 (de) 2009-11-30 2012-10-10 Ablynx N.V. Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
EP2400298B1 (de) * 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Verfahren zur Kultivierung einer einzigen B-Zelle und spezifische Antikörperproduktion
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
EA027835B1 (ru) 2010-07-09 2017-09-29 Круселл Холланд Б.В. Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
EP2422618A1 (de) 2010-08-27 2012-02-29 Technologie Integrale Ltd. Tiermodell zur Beurteilung der Wirksamkeit eines HIV-Impfstoffs
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
EP3699286A1 (de) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
EP2717898B1 (de) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Gerinnungsfördernde verbindungen und anwendungsverfahren dafür
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2756092A4 (de) * 2011-09-16 2015-10-28 Giovanni Amabile Verfahren zur herstellung von zellen, geweben und antikörpern
CN102850454B (zh) * 2011-09-27 2014-06-25 上海博沃生物科技有限公司 抗呼吸道合胞病毒的人单克隆抗体
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
KR20140091064A (ko) 2011-11-16 2014-07-18 암젠 인크 표피 성장 인자 결실 돌연변이체 vⅲ 관련 장애를 치료하는 방법
PL2802606T3 (pl) 2012-01-10 2018-09-28 Biogen Ma Inc. Udoskonalenie transportu cząsteczek terapeutycznych przez barierę krew-mózg
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
JPWO2014003137A1 (ja) * 2012-06-27 2016-06-02 旭化成メディカル株式会社 高アフィニティー抗体、及びその製造方法
CN104822828A (zh) * 2012-11-13 2015-08-05 弗·哈夫曼-拉罗切有限公司 抗原特异性浆母细胞的富集
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
CN104955324A (zh) 2013-01-29 2015-09-30 巴斯夫植物科学有限公司 表达hcp7的抗真菌植物
CA2897485A1 (en) 2013-01-29 2014-08-07 Basf Plant Science Company Gmbh Fungal resistant plants expressing hcp6
CN104981149B (zh) 2013-01-29 2022-03-04 巴斯夫植物科学有限公司 表达ein2的抗真菌植物
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
JP6462599B2 (ja) 2013-03-15 2019-01-30 シャアメン ユニバーシティ Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体
WO2014203988A1 (ja) * 2013-06-21 2014-12-24 アルフレッサファーマ株式会社 Ｒｓｖを検出するためのイムノクロマトグラフィー装置
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015048331A1 (en) 2013-09-25 2015-04-02 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP4331590A2 (de) 2013-10-29 2024-03-06 President and Fellows of Harvard College Verfahren und zusammensetzungen zur hemmung von oxidativem stress
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
PT3142750T (pt) 2014-05-13 2020-09-22 Univ Pennsylvania Composições que compreendem aav expressando construções de anticorpos duplos e suas utilizações
AU2015294834B2 (en) 2014-07-31 2021-04-29 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
MX2017001403A (es) 2014-07-31 2017-07-07 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
EP3253780A1 (de) 2015-02-04 2017-12-13 Basf Plant Science Company GmbH Verfahren zur erhöhung des widerstands gegen sojabohnenrost in transgenen pflanzen durch erhöhung des scopoletingehaltes
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
TWI772258B (zh) 2015-04-17 2022-08-01 德商安美基研究（慕尼黑）公司 Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
MA48852A (fr) 2015-05-13 2020-04-01 Univ Pennsylvania Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
LT3411402T (lt) 2016-02-03 2022-01-25 Amgen Research (Munich) Gmbh Bcma ir cd3 bispecifinis t ląsteles sužadinantis antikūno konstruktas
EA201891753A1 (ru) 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017175000A1 (en) * 2016-04-08 2017-10-12 Pulmocide Limited Compounds
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3054014A3 (de) 2016-05-10 2016-11-23 BASF Plant Science Company GmbH Benutzung einer fungizids auf transgenen pflanzen
EP3529270A2 (de) 2016-10-21 2019-08-28 Adimab, LLC Antikörper gegen das respiratorische synzytial-virus und verfahren zu deren erzeugung und verwendung
AU2017345759A1 (en) * 2016-10-21 2019-05-23 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP7265984B2 (ja) 2016-10-21 2023-04-27 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
KR20190132639A (ko) 2017-02-28 2019-11-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아데노-연관 바이러스(aav) 클레이드 f 벡터 및 이의 용도
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
UY37620A (es) 2017-02-28 2018-08-31 Univ Pennsylvania Vacunas contra la gripe mediadas por aav novedosas
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
UY37726A (es) 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
JP7166342B2 (ja) * 2017-11-30 2022-11-07 エフ．ホフマン－ラ ロシュ アーゲー Ｂ細胞培養法
BR112020011627A2 (pt) 2017-12-11 2020-11-17 Amgen Inc. processo de fabricação contínuo para produtos de anticorpos biespecíficos
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
MX2021001221A (es) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
UY38326A (es) 2018-08-03 2020-01-31 Amgen Inc Constructos de anticuerpos para cldn18.2 y cd3
WO2020043670A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
EP3938504A1 (de) 2019-03-11 2022-01-19 Basf Se Amylasen und verfahren zur herstellung und verwendung davon
CA3137494A1 (en) 2019-06-13 2020-12-17 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
AR120832A1 (es) 2019-12-20 2022-03-23 Amgen Inc Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
KR20220119467A (ko) 2019-12-27 2022-08-29 아피메트 게엠베하 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4118113A1 (de) 2020-03-12 2023-01-18 Amgen Inc. Verfahren zur behandlung und prophylaxe von crs bei patienten mit einer kombination aus bispezifischen antikörpern zur bindung an cds x-krebszellen und tnfalpha- oder il-6-hemmer
MX2022011632A (es) 2020-03-19 2022-10-13 Amgen Inc Anticuerpos contra mucina 17 y usos de los mismos.
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
CA3183693A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
JP2023547662A (ja) 2020-11-06 2023-11-13 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
MX2023005323A (es) 2020-11-06 2023-05-19 Amgen Inc Construcciones polipeptidicas que se unen a cd3.
EP4240768A2 (de) 2020-11-06 2023-09-13 Amgen Inc. Multitargeting bispezifischer antigenbindender moleküle mit erhöhter selektivität
AU2021373318A1 (en) 2020-11-06 2023-05-25 Amgen Inc. Antigen binding domain with reduced clipping rate
IL303236A (en) 2020-12-01 2023-07-01 Univ Pennsylvania New compounds with specific tissue-targeting motifs and preparations containing them
CA3215594A1 (en) 2021-04-02 2022-10-06 Agnieszka KIELCZEWSKA Mageb2 binding constructs
WO2022232289A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
IL308154A (en) 2021-07-30 2023-12-01 Affimed Gmbh Double structure antibodies
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA814386B (en) * 1980-07-01 1982-07-28 Nat Res Dev Production of viral antigens
DE3235924T1 (de) * 1981-03-06 1983-05-05 Celltech Ltd., Slough, Berkshire Monoklonaler antikoerper
US5340926A (en) * 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
US5332805A (en) * 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4717766A (en) * 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US4659563A (en) * 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US5271927A (en) * 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US5468606A (en) * 1989-09-18 1995-11-21 Biostar, Inc. Devices for detection of an analyte based upon light interference
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
DE3878468T2 (de) * 1987-12-23 1993-06-09 Upjohn Co Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US5137804A (en) * 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
US6093872A (en) * 1989-05-05 2000-07-25 Systemix, Inc. Extended human hematopoiesis in a heterologous host
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5279935A (en) * 1990-03-01 1994-01-18 Becton, Dickinson And Company Method of immunossay including deactivation of endogenous alkaline phosphatase
AU637914B2 (en) * 1990-05-03 1993-06-10 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
ES2113428T3 (es) * 1991-04-22 1998-05-01 Massachusetts Health Res Proceso de tamizado de muestras de plasma para determinar titulos de anticuerpos efectivos contra los virus respiratorios.
CA2109528A1 (en) * 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
CA2044940A1 (en) * 1991-06-10 1992-12-11 Inder M. Verma Transdominant negative proto-oncogene
WO1993005796A1 (en) * 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5418136A (en) * 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
WO1993019197A1 (en) * 1992-03-20 1993-09-30 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
CA2144043C (en) * 1992-09-16 2005-01-18 Dennis R. Burton Human neutralizing monoclonal antibodies to respiratory syncytial virus
JPH08508240A (ja) * 1993-01-12 1996-09-03 ジョージ グリスティーナ，アンソニー 受動免疫の直接的濃厚伝達のための方法および組成物
US5424189A (en) * 1993-03-05 1995-06-13 Kansas State University Research Foundation Bovine respiratory syncytial virus detection and primers
AU689489B2 (en) * 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Also Published As

Publication number Publication date
US5958765A (en) 1999-09-28
US5840298A (en) 1998-11-24
NZ310847A (en) 1999-05-28
US5811524A (en) 1998-09-22
CN1198648C (zh) 2005-04-27
NO975621D0 (no) 1997-12-04
US6537809B2 (en) 2003-03-25
AU717061B2 (en) 2000-03-16
ZA964434B (en) 1996-12-10
NO324047B1 (no) 2007-08-06
NZ335241A (en) 1999-07-29
US5939068A (en) 1999-08-17
US20040005323A1 (en) 2004-01-08
HK1015282A1 (en) 1999-10-15
EP2095827A1 (de) 2009-09-02
US6413771B1 (en) 2002-07-02
US20020001798A1 (en) 2002-01-03
JP3771267B2 (ja) 2006-04-26
US5955364A (en) 1999-09-21
JPH11507640A (ja) 1999-07-06
US20040076631A1 (en) 2004-04-22
EP0854730A1 (de) 1998-07-29
US5866125A (en) 1999-02-02
CN1192695A (zh) 1998-09-09
MXPA01011457A (es) 2005-09-08
MX9709778A (es) 1998-07-31
CA2223033A1 (en) 1996-12-19
KR100490687B1 (ko) 2005-08-05
MY137299A (en) 2009-01-30
US20020081723A1 (en) 2002-06-27
WO1996040252A1 (en) 1996-12-19
IL122404A0 (en) 1998-06-15
EP0854730B1 (de) 2009-05-13
AU6172096A (en) 1996-12-30
CO4480110A1 (es) 1997-07-09
UY24255A1 (es) 1996-06-18
ATE431159T1 (de) 2009-05-15
KR19990022645A (ko) 1999-03-25
BR9608884A (pt) 1999-07-06
NO975621L (no) 1998-02-04
AR003423A1 (es) 1998-08-05
EP0854730A4 (de) 2002-11-06
RS50157B (sr) 2009-05-06
CN1680447A (zh) 2005-10-12
YU36096A (sh) 1999-06-15
US20070082002A1 (en) 2007-04-12
SA96170384B1 (ar) 2006-07-31

Similar Documents

Publication Publication Date Title
DE69637930D1 (de) Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität
DE69637803D1 (de) Gaschromatographie-System mit geregeltem Probentransfer
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
CY2007012I1 (el) Αντισωματα anti-vegf
PT719859E (pt) Anticorpo monoclonal anti-alfa v-integrina
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
BR9606889A (pt) Toxinas proteicas inseticidas de photorhabdus
EP0870826A4 (de) Neue proteine und gegen diese gerichtete monoklonale antikörper
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
DE69626673D1 (de) Mit mikroprocess hergestellte ionendurchlässige verbundmembran für amperometrische messungen
ATE285474T1 (de) Haemophilus adhäsionsproteinen
DE69623589D1 (de) Heizsystem für fahrzeuge
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
ATE207935T1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
DE3886545T2 (de) Monoklonale human-antikörper, spezifisch für rh(d).
NO890116L (no) Monoklonale antistoffer.
IT8821702A0 (it) Nuovo anticorpo monoclonale.
DE69023717D1 (de) Monoklonaler Antikörper.
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
DK0919617T3 (da) Monoklonale antistoffer mod humant MP52
BR1100555B1 (pt) anticorpos monoclonais humanizados.
ZA954678B (en) Monoclonal antibody against cd44v6
SI0742795T1 (en) Immuno-stimulatory monoclonal antibodies
AU701885C (en) Monoclonal antibody active against CD44v6

Legal Events

Date Code Title Description
8364 No opposition during term of opposition